In colorectal cancer/melanoma, ALKBH5 accelerated expression of angiogenic genes, such as VEGFA and TGFβ1, which weakened the efficacy of GVAX/anti–PD-1 therapy. This evidence concerns the gene TGFB1 and melanoma.